EB-002
Pharmaceutical compound
From Wikipedia, the free encyclopedia
EB-002, also formerly known as EB-373, is a synthetic prodrug of the non-selective serotonin receptor agonist and serotonergic psychedelic psilocin which is under development for the treatment of neuropsychiatric disorders like depression and anxiety disorders.[1][2][3][4][5] It is taken orally.[1] The drug is under development by Enveric Biosciences.[1][2][3][5] As of November 2024, it is in the preclinical research stage of development.[1][2] In November 2024, Enveric Biosciences out-licensed EB-002 to MycoMedica Life Sciences in a deal that was estimated to be worth as much as $62 million.[3] Its exact chemical structure does not yet appear to have been disclosed.[1]
Other namesEB002; EB-373; EB373; Synthetic psilocin prodrug
| Clinical data | |
|---|---|
| Other names | EB002; EB-373; EB373; Synthetic psilocin prodrug |
| Routes of administration | Oral[1] |
| Drug class | Non-selective serotonin receptor agonist; Serotonin 5-HT2A receptor agonist; Serotonergic psychedelic; Hallucinogen |
See also
- Substituted tryptamine
- List of investigational hallucinogens and entactogens
- CT-4201, MSP-1014, and RE-109 (4-GO-DMT)
- Luvesilocin (4-GO-DiPT)
